Dec 19, 2022 Press Releases
PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...
Sep 12, 2022 Press Releases
PDF Version AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates significantly higher left ventricular uptake in ATTR-CMP participants than florbetapir SAN...
Sep 8, 2022 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...
Sep 6, 2022 Posters & Publications
AUTHORS: Wall, Jonathan1, Kennel, Stephen J1, Stuckey, Alan1, Powell, Dustin2, Guthrie, Spencer3, Martin, Emily1 1 University of Tennessee Graduate School of Medicine, USA 2 University of Tennessee Medical Center, USA 3 Attralus, Inc., USA Click Here to View...
Sep 6, 2022 Posters & Publications
AUTHORS: Kennel, Stephen J, Jackson, Joseph W, Stuckey, Alan C, Richey, Tina, Wall, Jonathan University of Tennessee Graduate School of Medicine, USA Click Here to View...
